SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MedImmune
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: James Mortensen who wrote (36)4/25/1997 7:06:00 PM
From: Shlepper   of 416
 
Hi Jim,

I think that there are lots of hands in the pie at Medimmune and it will take a while to sort through their obligations and such. I was tempted to sell when the stock rebounded to 17 but my wife enjoys reading their literature, and (hopefully, not wishfull thinking) thinks they will do well.

From what I gathered, Medimmune was in short supply of their mainstay drug. They were procastinating forever in choosing the site for their manufacturing operation, and then surprise - they couln't meet their needs. I still think that they will be successful in spite of themselves. I am a little concerned with Hochmayer(?) who seems to be enrichening himself a little (hopefully not at the expense of us little guys).

Since you're in the DC area, do you follow other local biotechs - Life Technologies is doing well. North American Vaccines, Guilford have also done well. Magainin was founded by a local Rockvillian but he's located in Philly.

Regards,

Shep
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News